Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Liquid and Reconstituted Caplacizumab Formulations
NCT02189733Phase 1Completed
- Sponsor
- Sanofi
- Start
- Jul 2014
- Primary completion
- Sep 2014
- Modality
- Nanobodies (VHH)
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of caplacizumab in thrombotic thrombocytopenic purpura (TTP) (2 arms), sponsored by Sanofi. Primary endpoint: Pharmacokinetics: concentration of caplacizumab in plasma. Started Jul 2014; status: completed.
02
Drugs
caplacizumab
03
Conditions
thrombotic thrombocytopenic purpura (TTP)
Beyond the preview
Go deeper on NCT02189733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02189733.